Autolus Therapeutics plc
AUTL Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$1.53
KIRA · Stoqly’s AI analyst, in plain words
- Autolus Therapeutics plc had $75.4M of revenue in fiscal 2025, up 644.9% on the year before.
- Its operating margin was −358.9%, up 2,026.8 pts: of every 100 in sales, about −359 is left after running the business.
- Autolus Therapeutics plc lost $288M in fiscal 2025.
- Free cash flow was −$303M in fiscal 2025, −401.4% of revenue.
Market cap
$407M
P/E
—
Revenue
$75.4M
Net income
−$288M
Free cash flow
−$303M
Operating margin
−358.9%
Autolus Therapeutics plc in 30 seconds · fiscal 2025
Are sales growing?
+644.9%
Yes. Sales grew 644.9% last year.
Does it make a profit?
−381.4%
No. It lost money last year.
Does profit turn into cash?
−401.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Autolus Therapeutics plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- Autolus Therapeutics plc
- CIK
- 0001730463
Autolus Therapeutics plc · AUTL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $1.7M | $10.1M | $75.4M |
| Revenue growth | — | — | — | 496.0% | 644.9% |
| Gross margin | — | — | 100.0% | −12.5% | −27.8% |
| Operating margin | — | — | −10,583.1% | −2,385.6% | −358.9% |
| Net income | −$142M | −$149M | −$208M | −$221M | −$288M |
| Net margin | — | — | −12,272.3% | −2,180.5% | −381.4% |
| Diluted EPS | −$1.97 | −$1.57 | −$1.20 | −$0.86 | −$1.08 |
| Cash | |||||
| Cash from operations | −$118M | −$112M | −$146M | −$206M | −$284M |
| Capital expenditure | $8.9M | $10.8M | $11.0M | $22.1M | $19.0M |
| Free cash flow | −$127M | −$123M | −$157M | −$228M | −$303M |
| FCF margin | — | — | −9,221.0% | −2,256.4% | −401.4% |
| Share count change | — | 31.8% | 83.1% | 46.7% | 4.3% |
| Debt and strength | |||||
| Cash and short-term investments | $310M | $382M | $240M | $588M | $301M |
| Shareholders' equity | $313M | $299M | $111M | $427M | $178M |
| Current ratio | — | 9.2x | 6.2x | 10.9x | 5.9x |
| Interest coverage | −127.6x | −16.1x | −4.0x | −26.0x | −7.4x |
| Returns and quality | |||||
| Return on equity | −45.4% | −48.6% | −101.6% | −81.9% | −95.0% |
| Return on tangible equity | −45.4% | −49.8% | −186.9% | −53.2% | −181.6% |
| Piotroski F-score | — | — | — | 4 | 2 |
| Altman Z'' | — | 0.3 | −6.4 | −0.4 | −6.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Autolus Therapeutics plc · AUTL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.53 a share, the company is worth $407M.
Source: SEC EDGAR XBRL filings (CIK 0001730463). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.